StocksMedium•10 November 2026•
1 min read
Spruce Biosciences Spins Off CRHX-101 Program into Adrenyx Biosciences
Key Facts
1Spruce Biosciences announced the separation of its CRHX-101 program into a newly formed, wholly-owned subsidiary named Adrenyx Biosciences, Inc.
Spruce Biosciences announced the separation of its CRHX-101 program into a newly formed, wholly-owned subsidiary named Adrenyx Biosciences, Inc. Benzinga reported that the move involves transitioning the drug program, formerly known as SPR-202, into the dedicated entity to streamline its development.
Spruce Biosciences, trading under the ticker SPRB, closed at $49.34 on November 9, 2026. The stock reached a day high of $51.29 and a low of $41 on that date, prior to the corporate restructuring of its clinical assets.